| 1 |
Huang G, Cao H, Liu G, Chen J. Role of androgen receptor signaling pathway-related lncRNAs in the prognosis and immune infiltration of breast cancer. Sci Rep 2022;12:20631. [PMID: 36450882 DOI: 10.1038/s41598-022-25231-0] [Reference Citation Analysis]
|
| 2 |
Jiang H, Ouyang Q, Yin Y, Tong Z, Shen K, Yuan Z, Geng C, Liu Y, Song G, Ran R, Li W, Qu Q, Wang M, Meng L, Tong Y, Li H. Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis. Eur J Cancer 2022;176:1-12. [PMID: 36182805 DOI: 10.1016/j.ejca.2022.08.025] [Reference Citation Analysis]
|
| 3 |
Metovic J, Borella F, D’alonzo M, Biglia N, Mangherini L, Tampieri C, Bertero L, Cassoni P, Castellano I. FOXA1 in Breast Cancer: A Luminal Marker with Promising Prognostic and Predictive Impact. Cancers 2022;14:4699. [DOI: 10.3390/cancers14194699] [Reference Citation Analysis]
|
| 4 |
Gjorgoska M, Rizner TL. Integration of androgen hormones in endometrial cancer biology. Trends Endocrinol Metab 2022;33:639-51. [PMID: 35879182 DOI: 10.1016/j.tem.2022.06.001] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Ravaioli S, Maltoni R, Pasculli B, Parrella P, Giudetti AM, Vergara D, Tumedei MM, Pirini F, Bravaccini S. Androgen receptor in breast cancer: The “5W” questions. Front Endocrinol 2022;13:977331. [DOI: 10.3389/fendo.2022.977331] [Reference Citation Analysis]
|
| 6 |
Vasiliou SK, Filippou PS, Clotet-Freixas S, Soosaipillai A, Batruch I, Viktor Tsianos F, Konvalinka A, Diamandis EP. Transcriptome profiling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line. Clin Proteomics 2022;19:14. [PMID: 35568821 DOI: 10.1186/s12014-022-09352-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Muhammad A, Forcados GE, Katsayal BS, Bako RS, Aminu S, Sadiq IZ, Abubakar MB, Yusuf AP, Malami I, Faruk M, Ibrahim S, Pase PA, Ahmed S, Abubakar IB, Abubakar M, Yates C. Potential epigenetic modifications implicated in triple- to quadruple-negative breast cancer transition: a review. Epigenomics 2022. [PMID: 35473304 DOI: 10.2217/epi-2022-0033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Abdelrazek MA, Nageb A, Barakat LA, Abouzid A, Elbaz R. BC-DETECT: combined detection of serum HE4 and TFF3 improves breast cancer diagnostic efficacy. Breast Cancer 2022. [PMID: 34994942 DOI: 10.1007/s12282-021-01328-8] [Reference Citation Analysis]
|
| 9 |
Mir MA, Aisha S, Mehraj U. Novel biomarkers in triple-negative breast cancer - role and perspective. Combinational Therapy in Triple Negative Breast Cancer 2022. [DOI: 10.1016/b978-0-323-96136-3.00004-2] [Reference Citation Analysis]
|
| 10 |
Ismail S, Kherbek H, Skef J, Zahlouk N, Abdulal R, Alshehabi Z. Triple-negative apocrine carcinoma as a rare cause of a breast lump in a Syrian female: a case report and review of the literature. BMC Women's Health 2021;21:396. [DOI: 10.1186/s12905-021-01539-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 11 |
Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI. Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. NPJ Precis Oncol 2021;5:92. [PMID: 34667258 DOI: 10.1038/s41698-021-00232-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 12 |
Seachrist DD, Anstine LJ, Keri RA. FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer. Cancers (Basel) 2021;13:5205. [PMID: 34680352 DOI: 10.3390/cancers13205205] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 13 |
Horr C, Buechler SA. Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression. NPJ Breast Cancer 2021;7:136. [PMID: 34642313 DOI: 10.1038/s41523-021-00345-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 14 |
Quinn CM, D'Arcy C, Wells C. Apocrine lesions of the breast. Virchows Arch 2021. [PMID: 34537861 DOI: 10.1007/s00428-021-03185-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 15 |
Cruz-Tapias P, Rubiano W, Rondón-Lagos M, Villegas VE, Rangel N. Intrinsic Subtypes and Androgen Receptor Gene Expression in Primary Breast Cancer. A Meta-Analysis. Biology (Basel) 2021;10:834. [PMID: 34571711 DOI: 10.3390/biology10090834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 16 |
Jahan N, Jones C, Rahman RL. Androgen receptor expression in breast cancer: Implications on prognosis and treatment, a brief review. Mol Cell Endocrinol 2021;531:111324. [PMID: 34000352 DOI: 10.1016/j.mce.2021.111324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 17 |
Ahram M, Bawadi R, Abdullah MS, Alsafadi DB, Abaza H, Abdallah S, Mustafa E. Involvement of β-catenin in Androgen-induced Mesenchymal Transition of Breast MDA-MB-453 Cancer Cells. Endocr Res 2021;46:114-28. [PMID: 33703980 DOI: 10.1080/07435800.2021.1895829] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 18 |
Leung JK, Tien AH, Sadar MD. Androgen Receptors in the Pathology of Disease. Nuclear Receptors 2021. [DOI: 10.1007/978-3-030-78315-0_16] [Reference Citation Analysis]
|
| 19 |
Yang P, Peng SJ, Dong YM, Yang L, Yang ZY, Hu XE, Bao GQ. Neoadjuvant targeted therapy for apocrine carcinoma of the breast: A case report. World J Clin Cases 2020; 8(23): 6036-6042 [PMID: 33344602 DOI: 10.12998/wjcc.v8.i23.6036] [Reference Citation Analysis]
|
| 20 |
Yang P, Peng S, Dong Y, Yang L, Yang Z, Hu X, Bao G. Neoadjuvant targeted therapy for apocrine carcinoma of the breast: A case report. WJCC 2020;8:6031-6. [DOI: 10.12998/wjcc.v8.i23.6031] [Reference Citation Analysis]
|
| 21 |
Tripathy D, Agarwal S, Biala A, Rath S, Mittal R. Primary De novo ductal adenocarcinoma of the lacrimal gland. Ann Diagn Pathol 2021;50:151651. [PMID: 33186791 DOI: 10.1016/j.anndiagpath.2020.151651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 22 |
Al-Othman N, Ahram M, Alqaraleh M. Role of androgen and microRNA in triple-negative breast cancer. Breast Dis 2020;39:15-27. [PMID: 31839601 DOI: 10.3233/BD-190416] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 23 |
Michmerhuizen AR, Spratt DE, Pierce LJ, Speers CW. ARe we there yet? Understanding androgen receptor signaling in breast cancer. NPJ Breast Cancer 2020;6:47. [PMID: 33062889 DOI: 10.1038/s41523-020-00190-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 24 |
Govindan S, Siraganahalli Eswaraiah M, Basavaraj C, Adinarayan M, Sankaran S, Bakre M. Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients. BMC Cancer 2020;20:745. [PMID: 32778063 DOI: 10.1186/s12885-020-07218-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 25 |
Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI. Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations.. [DOI: 10.1101/2020.07.25.20146431] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 26 |
Rangel N, Rondon-Lagos M, Annaratone L, Aristizábal-Pachon AF, Cassoni P, Sapino A, Castellano I. AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors. Cells 2020;9:E1064. [PMID: 32344660 DOI: 10.3390/cells9041064] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 27 |
Sa-Nguanraksa D, Pongthong W, Samarnthai N, Mitpakdi K, Chuangsuwanich T, Limjindaporn T, Kulprom A, O-Charoenrat P. Expression of androgen receptor and its regulatory molecule Lin28 in non-luminal subtype breast cancer. Mol Clin Oncol 2020;12:511-8. [PMID: 32382417 DOI: 10.3892/mco.2020.2029] [Reference Citation Analysis]
|
| 28 |
Liu J, Xu C, Xu D, Cao L, Xue H, Meng Q, Niu Y. The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer. Virchows Arch 2020;477:279-89. [PMID: 32086588 DOI: 10.1007/s00428-020-02773-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 29 |
Kanai A, McNamara KM, Iwabuchi E, Miki Y, Onodera Y, Guestini F, Khalid F, Sagara Y, Ohi Y, Rai Y, Yamaguchi R, Tanaka M, Miyashita M, Ishida T, Sasano H. Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling. Breast Cancer Res Treat 2020;180:97-110. [PMID: 31989378 DOI: 10.1007/s10549-020-05523-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 30 |
Zakaria F, El-mashad N, Mohamed D. Androgen receptor expression as a prognostic and predictive marker in triple-negative breast cancer patients. Alexandria Journal of Medicine 2016;52:131-40. [DOI: 10.1016/j.ajme.2015.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 31 |
Venema CM, Bense RD, Steenbruggen TG, Nienhuis HH, Qiu SQ, van Kruchten M, Brown M, Tamimi RM, Hospers GAP, Schröder CP, Fehrmann RSN, de Vries EGE. Consideration of breast cancer subtype in targeting the androgen receptor. Pharmacol Ther 2019;200:135-47. [PMID: 31077689 DOI: 10.1016/j.pharmthera.2019.05.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 32 |
Bandini E, Fanini F. MicroRNAs and Androgen Receptor: Emerging Players in Breast Cancer. Front Genet 2019;10:203. [PMID: 30941159 DOI: 10.3389/fgene.2019.00203] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 33 |
Vasiliou SK, Diamandis EP. Androgen receptor: A promising therapeutic target in breast cancer. Crit Rev Clin Lab Sci 2019;56:200-23. [PMID: 30821186 DOI: 10.1080/10408363.2019.1575643] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 34 |
Secreto G, Girombelli A, Krogh V. Androgen excess in breast cancer development: implications for prevention and treatment. Endocr Relat Cancer 2019;26:R81-94. [PMID: 30403656 DOI: 10.1530/ERC-18-0429] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 35 |
Shi Y, Yang F, Huang D, Guan X. Androgen blockade based clinical trials landscape in triple negative breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2018;1870:283-90. [DOI: 10.1016/j.bbcan.2018.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 36 |
D'Arcy C, Quinn CM. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast. J Clin Pathol 2019;72:7-11. [PMID: 30425121 DOI: 10.1136/jclinpath-2018-205485] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 37 |
Al-othman N, Hammad H, Ahram M. Dihydrotestosterone regulates expression of CD44 via miR-328-3p in triple-negative breast cancer cells. Gene 2018;675:128-35. [DOI: 10.1016/j.gene.2018.06.094] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 38 |
Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic Markers in Triple-Negative Breast Cancer. Clin Breast Cancer 2018;18:e841-50. [PMID: 30146351 DOI: 10.1016/j.clbc.2018.07.023] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 15.2] [Reference Citation Analysis]
|
| 39 |
Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del Mastro L, De Laurentiis M, Puglisi F, Arpino G. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treat Rev 2018;68:102-10. [PMID: 29940524 DOI: 10.1016/j.ctrv.2018.06.005] [Cited by in Crossref: 107] [Cited by in F6Publishing: 118] [Article Influence: 21.4] [Reference Citation Analysis]
|
| 40 |
Liu X, Feng C, Liu J, Cao L, Xiang G, Liu F, Wang S, Jiao J, Niu Y. Androgen receptor and heat shock protein 27 co-regulate the malignant potential of molecular apocrine breast cancer. J Exp Clin Cancer Res 2018;37:90. [PMID: 29699584 DOI: 10.1186/s13046-018-0762-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 41 |
Bronte G, Rocca A, Ravaioli S, Puccetti M, Tumedei MM, Scarpi E, Andreis D, Maltoni R, Sarti S, Cecconetto L, Fedeli A, Pietri E, De Simone V, Asioli S, Amadori D, Bravaccini S. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? BMC Cancer. 2018;18:348. [PMID: 29587674 DOI: 10.1186/s12885-018-4239-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 42 |
Shen H, Zhao L, Feng X, Xu C, Li C, Niu Y. Lin28A activates androgen receptor via regulation of c-myc and promotes malignancy of ER-/Her2+ breast cancer. Oncotarget 2016;7:60407-18. [PMID: 27494865 DOI: 10.18632/oncotarget.11004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 43 |
Lyons TG, Traina TA. Androgen Receptor-Targeted Therapy for Breast Cancer. Curr Breast Cancer Rep 2017;9:242-250. [DOI: 10.1007/s12609-017-0261-8] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 44 |
He L, Du Z, Xiong X, Ma H, Zhu Z, Gao H, Cao J, Li T, Li H, Yang K, Chen G, Richer JK, Gu H. Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer. Sci Rep 2017;7:14584. [PMID: 29109513 DOI: 10.1038/s41598-017-14607-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 45 |
Mina A, Yoder R, Sharma P. Targeting the androgen receptor in triple-negative breast cancer: current perspectives. Onco Targets Ther 2017;10:4675-85. [PMID: 29033586 DOI: 10.2147/OTT.S126051] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 46 |
Park S, Koh E, Koo JS, Kim SI, Park BW, Kim KS. Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptor-positive breast cancers. Oncotarget 2017;8:82940-55. [PMID: 29137314 DOI: 10.18632/oncotarget.20937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 47 |
Naderi A. C1orf64 is a novel androgen receptor target gene and coregulator that interacts with 14-3-3 protein in breast cancer. Oncotarget 2017;8:57907-33. [PMID: 28915724 DOI: 10.18632/oncotarget.17826] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 48 |
Rahim B, O'Regan R. AR Signaling in Breast Cancer. Cancers (Basel) 2017;9:E21. [PMID: 28245550 DOI: 10.3390/cancers9030021] [Cited by in Crossref: 58] [Cited by in F6Publishing: 66] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 49 |
Vranic S, Feldman R, Gatalica Z. Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers. Bosn J Basic Med Sci 2017;17:9-11. [PMID: 28027454 DOI: 10.17305/bjbms.2016.1811] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 50 |
Yuan Z, Chen D, Chen X, Yang H, Wei Y. Overexpression of trefoil factor 3 (TFF3) contributes to the malignant progression in cervical cancer cells. Cancer Cell Int 2017;17:7. [PMID: 28070169 DOI: 10.1186/s12935-016-0379-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 51 |
Hickey TE, Irvine CM, Dvinge H, Tarulli GA, Hanson AR, Ryan NK, Pickering MA, Birrell SN, Hu DG, Mackenzie PI, Russell R, Caldas C, Raj GV, Dehm SM, Plymate SR, Bradley RK, Tilley WD, Selth LA. Expression of androgen receptor splice variants in clinical breast cancers. Oncotarget 2015;6:44728-44. [PMID: 26554309 DOI: 10.18632/oncotarget.6296] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 52 |
Thornton KJ, Kamange-Sollo E, White ME, Dayton WR. Role of G protein-coupled receptors (GPCR), matrix metalloproteinases 2 and 9 (MMP2 and MMP9), heparin-binding epidermal growth factor-like growth factor (hbEGF), epidermal growth factor receptor (EGFR), erbB2, and insulin-like growth factor 1 receptor (IGF-1R) in trenbolone acetate-stimulated bovine satellite cell proliferation. J Anim Sci 2015;93:4291-301. [PMID: 26440329 DOI: 10.2527/jas.2015-9191] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 53 |
Wasserman JK, Williams PA, Islam S, Robertson SJ. GATA-3 expression is not associated with complete pathological response in triple negative breast cancer patients treated with neoadjuvant chemotherapy. Pathology - Research and Practice 2016;212:539-44. [DOI: 10.1016/j.prp.2016.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 54 |
Guiu S, Charon-Barra C, Vernerey D, Fumoleau P, Campone M, Spielmann M, Roché H, Mesleard C, Arnould L, Lemonnier J, Lacroix-Triki M. Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial. Future Oncol 2015;11:2283-97. [PMID: 26260807 DOI: 10.2217/fon.15.102] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 55 |
Zhao L, Niu F, Shen H, Liu X, Chen L, Niu Y. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer. Virchows Arch 2016;468:687-96. [PMID: 27026268 DOI: 10.1007/s00428-016-1930-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 56 |
Shen H, Yang Y, Zhao L, Yuan J, Niu Y. Lin28A and androgen receptor expression in ER-/Her2+ breast cancer. Breast Cancer Res Treat 2016;156:135-47. [PMID: 26944953 DOI: 10.1007/s10549-016-3744-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 57 |
Lau WH, Pandey V, Kong X, Wang XN, Wu Z, Zhu T, Lobie PE. Trefoil Factor-3 (TFF3) Stimulates De Novo Angiogenesis in Mammary Carcinoma both Directly and Indirectly via IL-8/CXCR2. PLoS One 2015;10:e0141947. [PMID: 26559818 DOI: 10.1371/journal.pone.0141947] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 58 |
Munoz J, Wheler JJ, Kurzrock R. Androgen receptors beyond prostate cancer: an old marker as a new target. Oncotarget 2015;6:592-603. [PMID: 25595907 DOI: 10.18632/oncotarget.2831] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 59 |
Singh P, Bast F. Screening of multi-targeted natural compounds for receptor tyrosine kinases inhibitors and biological evaluation on cancer cell lines, in silico and in vitro. Med Oncol 2015;32:233. [PMID: 26298529 DOI: 10.1007/s12032-015-0678-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 60 |
Gromov P, Espinoza JA, Gromova I. Molecular and diagnostic features of apocrine breast lesions. Expert Review of Molecular Diagnostics 2015;15:1011-22. [DOI: 10.1586/14737159.2015.1057125] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 61 |
Singh P, Bast F. Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and androgen receptor; in silico and in vitro. Invest New Drugs 2015;33:575-93. [PMID: 25895100 DOI: 10.1007/s10637-015-0240-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 62 |
Mehta J, Asthana S, Mandal CC, Saxena S. A molecular analysis provides novel insights into androgen receptor signalling in breast cancer. PLoS One 2015;10:e0120622. [PMID: 25781993 DOI: 10.1371/journal.pone.0120622] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 63 |
Naderi A, Vanneste M. Prolactin-induced protein is required for cell cycle progression in breast cancer. Neoplasia 2014;16:329-42.e1-14. [PMID: 24862759 DOI: 10.1016/j.neo.2014.04.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 64 |
Naderi A. Prolactin-induced protein in breast cancer. Adv Exp Med Biol 2015;846:189-200. [PMID: 25472539 DOI: 10.1007/978-3-319-12114-7_8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 65 |
Dittrich A, Gautrey H, Browell D, Tyson-Capper A. The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web. J Mammary Gland Biol Neoplasia 2014;19:253-70. [PMID: 25544707 DOI: 10.1007/s10911-014-9329-5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 66 |
Gromov P, Espinoza JA, Talman ML, Honma N, Kroman N, Timmermans Wielenga V, Moreira JM, Gromova I. FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast. PLoS One 2014;9:e112024. [PMID: 25389781 DOI: 10.1371/journal.pone.0112024] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 67 |
Naderi A. Coagulation factor VII is regulated by androgen receptor in breast cancer. Exp Cell Res 2015;331:239-50. [PMID: 25447311 DOI: 10.1016/j.yexcr.2014.10.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 68 |
Pandey V, Wu ZS, Zhang M, Li R, Zhang J, Zhu T, Lobie PE. Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Res 2014;16:429. [PMID: 25266665 DOI: 10.1186/s13058-014-0429-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 69 |
McNamara KM, Moore NL, Hickey TE, Sasano H, Tilley WD. Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer 2014;21:T161-81. [PMID: 24951107 DOI: 10.1530/ERC-14-0243] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 10.4] [Reference Citation Analysis]
|
| 70 |
Fioretti FM, Sita-Lumsden A, Bevan CL, Brooke GN. Revising the role of the androgen receptor in breast cancer. J Mol Endocrinol 2014;52:R257-65. [PMID: 24740738 DOI: 10.1530/JME-14-0030] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 71 |
Qabaja A, Jarada T, Elsheikh A, Alhajj R. Prediction of gene-based drug indications using compendia of public gene expression data and PubMed abstracts. J Bioinform Comput Biol 2014;12:1450007. [PMID: 24969745 DOI: 10.1142/S0219720014500073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 72 |
Tsang JY, Ni YB, Chan SK, Shao MM, Law BK, Tan PH, Tse GM. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers. Ann Surg Oncol 2014;21:2218-28. [PMID: 24639191 DOI: 10.1245/s10434-014-3629-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 73 |
Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer 2014;14:187-98. [PMID: 24561445 DOI: 10.1038/nrc3678] [Cited by in Crossref: 123] [Cited by in F6Publishing: 129] [Article Influence: 13.7] [Reference Citation Analysis]
|
| 74 |
Gerhard R, Costa JL, Schmitt F. Benign and malignant apocrine lesions of the breast. Expert Review of Anticancer Therapy 2014;12:215-21. [DOI: 10.1586/era.11.213] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 75 |
Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:djt319. [PMID: 24273215 DOI: 10.1093/jnci/djt319] [Cited by in Crossref: 216] [Cited by in F6Publishing: 229] [Article Influence: 21.6] [Reference Citation Analysis]
|
| 76 |
Higa GM, Fell RG. Sex hormone receptor repertoire in breast cancer. Int J Breast Cancer. 2013;2013:284036. [PMID: 24324894 DOI: 10.1155/2013/284036] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 77 |
Yue L, Xiang J, Shen Z, Wang Z, Yao Y, Zhou Q, Ding A, Qiu W. Inhibition of ErbB-2 induces TFF3 downregulation in breast cancer cell lines. APMIS 2014;122:628-35. [PMID: 24164280 DOI: 10.1111/apm.12203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 78 |
Takagi K, Ito S, Miyazaki T, Miki Y, Shibahara Y, Ishida T, Watanabe M, Inoue S, Sasano H, Suzuki T. Amyloid precursor protein in human breast cancer: an androgen-induced gene associated with cell proliferation. Cancer Sci 2013;104:1532-8. [PMID: 23889773 DOI: 10.1111/cas.12239] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 79 |
Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; Translational Breast Cancer Research Consortium (TBCRC 011). Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res 2013;19:5505-12. [PMID: 23965901 DOI: 10.1158/1078-0432.CCR-12-3327] [Cited by in Crossref: 433] [Cited by in F6Publishing: 466] [Article Influence: 43.3] [Reference Citation Analysis]
|
| 80 |
Xu C, Yue L, Wei H, Zhao W, Sui A, Wang X, Qiu W. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma. Pathology - Research and Practice 2013;209:479-85. [DOI: 10.1016/j.prp.2013.04.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 81 |
Campagnoli C, Pasanisi P, Castellano I, Abbà C, Brucato T, Berrino F. Postmenopausal breast cancer, androgens, and aromatase inhibitors. Breast Cancer Res Treat 2013;139:1-11. [PMID: 23572296 DOI: 10.1007/s10549-013-2505-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 82 |
Hodgson MC, Vanostran G, Alghamdi S, Poppiti RJ, Agoulnik AI, Agoulnik IU. Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice. PLoS One 2013;8:e60455. [PMID: 23593223 DOI: 10.1371/journal.pone.0060455] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 83 |
Secreto G, Venturelli E, Meneghini E, Carcangiu ML, Paolini B, Agresti R, Pellitteri C, Berrino F, Gion M, Cogliati P, Saragò G, Micheli A. Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers. BMC Cancer 2012;12:599. [PMID: 23241075 DOI: 10.1186/1471-2407-12-599] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 84 |
Takagi K, Miki Y, Onodera Y, Nakamura Y, Ishida T, Watanabe M, Inoue S, Sasano H, Suzuki T. Krüppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens. Endocr Relat Cancer 2012;19:741-50. [PMID: 22936544 DOI: 10.1530/ERC-12-0017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 85 |
Naderi A, Meyer M, Dowhan DH. Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia 2012;14:283-96. [PMID: 22577344 DOI: 10.1593/neo.12294] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 86 |
Moore NL, Buchanan G, Harris JM, Selth LA, Bianco-Miotto T, Hanson AR, Birrell SN, Butler LM, Hickey TE, Tilley WD. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocr Relat Cancer 2012;19:599-613. [PMID: 22719059 DOI: 10.1530/ERC-12-0065] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 87 |
Naderi A, Meyer M. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer. Breast Cancer Res. 2012;14:R111. [PMID: 22817771 DOI: 10.1186/bcr3232] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 88 |
Hickey TE, Robinson JL, Carroll JS, Tilley WD. Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol 2012;26:1252-67. [PMID: 22745190 DOI: 10.1210/me.2012-1107] [Cited by in Crossref: 199] [Cited by in F6Publishing: 206] [Article Influence: 18.1] [Reference Citation Analysis]
|
| 89 |
Bernardo GM, Keri RA. FOXA1: a transcription factor with parallel functions in development and cancer. Biosci Rep 2012;32:113-30. [PMID: 22115363 DOI: 10.1042/BSR20110046] [Cited by in Crossref: 128] [Cited by in F6Publishing: 137] [Article Influence: 11.6] [Reference Citation Analysis]
|
| 90 |
Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA. FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene 2013;32:554-63. [PMID: 22391567 DOI: 10.1038/onc.2012.62] [Cited by in Crossref: 98] [Cited by in F6Publishing: 104] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 91 |
Gucalp A, Traina TA. The Androgen Receptor in Breast Cancer: Biology and Treatment Considerations. Curr Breast Cancer Rep 2012;4:56-65. [DOI: 10.1007/s12609-011-0059-z] [Reference Citation Analysis]
|
| 92 |
Bhargava R. Apocrine Carcinoma of the Breast. Breast Pathology 2012. [DOI: 10.1016/b978-1-4377-0604-8.00026-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 93 |
Lehmann-che J. Cancers du sein hormono-dépendants: quels biomarqueurs tissulaires utiles dans la prise en charge ? Bio trib mag 2011;39:29-34. [DOI: 10.1007/s11834-011-0052-x] [Reference Citation Analysis]
|
| 94 |
Vranic S, Gatalica Z, Wang ZY. Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies. Oncol Lett 2011;2:1131-7. [PMID: 22121396 DOI: 10.3892/ol.2011.375] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 95 |
Zheng Y, Izumi K, Yao JL, Miyamoto H. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr Relat Cancer 2011;18:451-64. [PMID: 21613411 DOI: 10.1530/ERC-11-0010] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 96 |
Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin AL, Feugeas JP, Bièche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de Thé H, Theillet C. A refined molecular taxonomy of breast cancer. Oncogene 2012;31:1196-206. [PMID: 21785460 DOI: 10.1038/onc.2011.301] [Cited by in Crossref: 192] [Cited by in F6Publishing: 200] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 97 |
Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2011;24:924-31. [PMID: 21552212 DOI: 10.1038/modpathol.2011.54] [Cited by in Crossref: 218] [Cited by in F6Publishing: 225] [Article Influence: 18.2] [Reference Citation Analysis]
|
| 98 |
Chia KM, Liu J, Francis GD, Naderi A. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia 2011;13:154-66. [PMID: 21403841 DOI: 10.1593/neo.101324] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 99 |
Naderi A, Chia KM, Liu J. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res 2011;13:R36. [PMID: 21457548 DOI: 10.1186/bcr2858] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 100 |
Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, Miller LD, Liu ET, Mertani HC, Zhu T, Grandison PM, Liu DX, Lobie PE. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia 2010;12:1041-53. [PMID: 21170268 DOI: 10.1593/neo.10916] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 101 |
Rehemtulla A. Dinosaurs and ancient civilizations: reflections on the treatment of cancer. Neoplasia 2010;12:957-68. [PMID: 21170260 DOI: 10.1593/neo.101588] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 102 |
Rickman DS, Chen YB, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR, Sircar K, Chinnaiyan AM, Bismar TA, Rubin MA, Demichelis F. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 2010;12:1031-40. [PMID: 21170267 DOI: 10.1593/neo.10866] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 103 |
Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW, Lee KS. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 2011;22:1755-62. [PMID: 21310761 DOI: 10.1093/annonc/mdq678] [Cited by in Crossref: 139] [Cited by in F6Publishing: 147] [Article Influence: 11.6] [Reference Citation Analysis]
|
| 104 |
Micello D, Marando A, Sahnane N, Riva C, Capella C, Sessa F. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Arch 2010;457:467-76. [DOI: 10.1007/s00428-010-0964-y] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 105 |
Banneau G, Guedj M, MacGrogan G, de Mascarel I, Velasco V, Schiappa R, Bonadona V, David A, Dugast C, Gilbert-Dussardier B, Ingster O, Vabres P, Caux F, de Reynies A, Iggo R, Sevenet N, Bonnet F, Longy M. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res 2010;12:R63. [PMID: 20712882 DOI: 10.1186/bcr2626] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 106 |
Notas G, Pelekanou V, Castanas E, Kampa M. Conjugated and non-conjugated androgens differentially modulate specific early gene transcription in breast cancer in a cell-specific manner. Steroids 2010;75:611-8. [DOI: 10.1016/j.steroids.2009.10.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 107 |
Naderi A, Liu J. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. Cancer Lett. 2010;298:74-87. [PMID: 20605569 DOI: 10.1016/j.canlet.2010.06.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 108 |
Vranic S, Tawfik O, Palazzo J, Bilalovic N, Eyzaguirre E, Lee LM, Adegboyega P, Hagenkord J, Gatalica Z. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 2010;23:644-53. [PMID: 20208479 DOI: 10.1038/modpathol.2010.50] [Cited by in Crossref: 81] [Cited by in F6Publishing: 86] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 109 |
Rehemtulla A. The War on Cancer rages on. Neoplasia 2009;11:1252-63. [PMID: 20019833 DOI: 10.1593/neo.91866] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 110 |
Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010;23:205-12. [PMID: 19898421 DOI: 10.1038/modpathol.2009.159] [Cited by in Crossref: 283] [Cited by in F6Publishing: 301] [Article Influence: 21.8] [Reference Citation Analysis]
|
| 111 |
Hu Y, Sun H, Owens RT, Wu J, Chen YQ, Berquin IM, Perry D, O'Flaherty JT, Edwards IJ. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 2009;11:1042-53. [PMID: 19794963 DOI: 10.1593/neo.09760] [Cited by in Crossref: 77] [Cited by in F6Publishing: 81] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 112 |
Werner J, Ouellet JD, Cheng CS, Ju Y, Law RD. Pulp and paper mill effluents induce distinct gene expression changes linked to androgenic and estrogenic responses in the fathead minnow ( Pimephales promelas ). Environmental Toxicology and Chemistry 2010;29:430-9. [DOI: 10.1002/etc.48] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 113 |
Graham TR, Yacoub R, Taliaferro-Smith L, Osunkoya AO, Odero-Marah VA, Liu T, Kimbro KS, Sharma D, O'Regan RM. Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res Treat 2010;123:139-47. [PMID: 19921427 DOI: 10.1007/s10549-009-0623-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 114 |
Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010;21:488-92. [PMID: 19887463 DOI: 10.1093/annonc/mdp510] [Cited by in Crossref: 240] [Cited by in F6Publishing: 253] [Article Influence: 17.1] [Reference Citation Analysis]
|
| 115 |
Sanga S, Broom BM, Cristini V, Edgerton ME. Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Med Genomics 2009;2:59. [PMID: 19747394 DOI: 10.1186/1755-8794-2-59] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 116 |
Rehemtulla A. Neoplasia: the second decade. Neoplasia 2008;10:1314-24. [PMID: 19048110 DOI: 10.1593/neo.81372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 117 |
Nakshatri H, Badve S. FOXA1 in breast cancer. Expert Rev Mol Med 2009;11:e8. [PMID: 19261198 DOI: 10.1017/S1462399409001008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 118 |
Sutherland R. Basic science: (JUNE 2008). Breast Cancer Online 2008;11:e18. [DOI: 10.1017/s1470903108008432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
